NOVAVAX INC (NVAX)

US6700024010 - Common Stock

4.85  +0.14 (+2.97%)

Premarket: 4.78 -0.07 (-1.44%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NVAX. NVAX was compared to 592 industry peers in the Biotechnology industry. NVAX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, NVAX is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

In the past year NVAX has reported negative net income.
NVAX had a negative operating cash flow in the past year.
In the past 5 years NVAX always reported negative net income.
NVAX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

NVAX's Return On Assets of -30.33% is fine compared to the rest of the industry. NVAX outperforms 72.96% of its industry peers.
Industry RankSector Rank
ROA -30.33%
ROE N/A
ROIC N/A
ROA(3y)-42.37%
ROA(5y)-46.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 65.11%, NVAX belongs to the best of the industry, outperforming 82.48% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for NVAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

NVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NVAX has more shares outstanding
Compared to 5 years ago, NVAX has more shares outstanding
The debt/assets ratio for NVAX has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -4.39, we must say that NVAX is in the distress zone and has some risk of bankruptcy.
NVAX has a worse Altman-Z score (-4.39) than 63.95% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.39
ROIC/WACCN/A
WACC8.39%

2.3 Liquidity

NVAX has a Current Ratio of 0.70. This is a bad value and indicates that NVAX is not financially healthy enough and could expect problems in meeting its short term obligations.
NVAX's Current ratio of 0.70 is on the low side compared to the rest of the industry. NVAX is outperformed by 93.20% of its industry peers.
A Quick Ratio of 0.67 indicates that NVAX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.67, NVAX is doing worse than 93.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.7
Quick Ratio 0.67

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.17% over the past year.
NVAX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -50.36%.
NVAX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 95.67% yearly.
EPS 1Y (TTM)34.17%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q36.84%
Revenue 1Y (TTM)-50.36%
Revenue growth 3Y27.41%
Revenue growth 5Y95.67%
Revenue growth Q2Q-18.48%

3.2 Future

Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.15% on average per year.
Based on estimates for the next years, NVAX will show a small growth in Revenue. The Revenue will grow by 5.98% on average per year.
EPS Next Y83.18%
EPS Next 2Y42.74%
EPS Next 3Y29.15%
EPS Next 5Y15.15%
Revenue Next Year-15.99%
Revenue Next 2Y-3.15%
Revenue Next 3Y2.85%
Revenue Next 5Y5.98%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

NVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

NVAX's earnings are expected to grow with 29.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.74%
EPS Next 3Y29.15%

0

5. Dividend

5.1 Amount

NVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NOVAVAX INC

NASDAQ:NVAX (3/27/2024, 8:00:03 PM)

Premarket: 4.78 -0.07 (-1.44%)

4.85

+0.14 (+2.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap678.76M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.33%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 65.11%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.7
Quick Ratio 0.67
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)34.17%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y83.18%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-50.36%
Revenue growth 3Y27.41%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y